SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-113960
Filing Date
2024-10-10
Accepted
2024-10-10 08:30:08
Documents
11
Period of Report
2024-10-04
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tcrt-20241004.htm   iXBRL 8-K 60869
  Complete submission text file 0000950170-24-113960.txt   186646

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20241004.xsd EX-101.SCH 31856
13 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20241004_htm.xml XML 4710
Mailing Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

IRS No.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 241363873
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)